Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-02-12
2008-11-18
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S465000
Reexamination Certificate
active
07452913
ABSTRACT:
The present invention relates to polymorphs of the 3-pyrrole substituted 2-indolinone compound 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide.
REFERENCES:
patent: 6333333 (2001-12-01), Bishop et al.
patent: 6339100 (2002-01-01), Longley
patent: 6451838 (2002-09-01), Moon et al.
patent: 6482848 (2002-11-01), Moon et al.
patent: 6573293 (2003-06-01), Tang et al.
patent: 6710067 (2004-03-01), Moon et al.
patent: 2002/0010203 (2002-01-01), Lipson et al.
patent: 2003/0100555 (2003-05-01), Sun et al.
patent: 2003/0130280 (2003-07-01), O'Farrell et al.
patent: 2004/0063773 (2004-04-01), Tang et al.
patent: WO01/60814 (2001-08-01), None
patent: WO02081466 (2002-10-01), None
US pharmacopia #23, national formulary #18 (1995).
Polymorphism in Pharmaceutical Solids, Brittain (1999).
Rouhi, “The Right Stuff,” Chem. & Engineering News (2003).
C. A. London, “Kinase Inhibitors in the Treatment of Canine Cancer”. Proceedings of Annual Canine Cancer Conference, 2002.
C. A. London, “Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosin Kinase Inhibitor, in Dogs with Spontaneous Malignancies,” Clinical Cancer Research, vol. 9, pp. 2755-2768, 2003.
Yongsheng Ma, et al., “Clustering of activating mutations in c-KIT's Juxtamembrane Coding Region in Canine Mast Cell Neoplasms,” J Invest Dermatol 1999, pp. 165-170.
Yongsheng Ma, et al., “Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells,” J Invest Dermatol 2000, pp. 392-394.
N.K Pryer et al, “Proof of Target for SU11654: Inhibition of KIT Phosphorylation in Canine Mast Cell Tumors”, Clinical Cancer Research, vol. 9, pp. 5729-5734, 2003.
Foster Todd P.
Han Fusen
Hawley Michael
Sun Changquan
Thamann Tom
Barker Michael P
Gumbleton Timothy J.
Pharmacia & Upjohn Company
Saeed Kamal
LandOfFree
Polymorphs of pyrrole substituted 2-indolinone protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphs of pyrrole substituted 2-indolinone protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphs of pyrrole substituted 2-indolinone protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4043354